ストックスクリーナーアプリを入手
78.96
0.34%
-0.42
前日終値:
$79.38
開ける：
$79.94
24時間の取引高:
78,027
Relative Volume:
0.05
時価総額：
$14.37B
収益：
$342.96M
当期純損益:
$-864.29M
株価収益率:
-14.23
EPS:
-5.55
ネットキャッシュフロー:
$-636.03M
1週間 パフォーマンス:
+2.75%
1か月 パフォーマンス:
+2.08%
6か月 パフォーマンス:
+8.76%
1年 パフォーマンス:
+193.00%
1日の値動き範囲:
$78.76
$80.00
1週間の範囲:
$76.80
$81.50
52週間の値動き範囲:
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
INSM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
78.92 | 14.37B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.94 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
655.00 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
289.23 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
610.93 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
255.17 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference - Yahoo Finance
Insmed’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Insmed’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Insmed reports preclinical data on INS-1201 for DMD - BioWorld Online
Insmed CEO William Lewis sells $1.97 million in stock By Investing.com - Investing.com Australia
Insmed’s stock should triple after positive drug trial data, analyst says - MSN
H.C. Wainwright maintains Buy on Insmed stock, $90 target By Investing.com - Investing.com Canada
Insmed CEO William Lewis sells $1.97 million in stock - Investing.com India
Expert Outlook: Insmed Through The Eyes Of 13 Analysts - Benzinga
RBC maintains Outperform on Insmed stock, price target at $100 By Investing.com - Investing.com Canada
Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Truist maintains Buy on Insmed stock, sees PAH data as positive - Investing.com Australia
US Bancorp DE Boosts Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World
Truist maintains Buy on Insmed stock, sees PAH data as positive By Investing.com - Investing.com South Africa
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch By Investing.com - Investing.com South Africa
Insider Sell: Roger Adsett Sells 42,975 Shares of Insmed Inc (IN - GuruFocus.com
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch - Investing.com
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC - Defense World
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -March 10, 2025 at 08:01 am EDT - Marketscreener.com
Insmed Expands Team with Stock Options Grant to 18 New Hires - StockTitan
UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00 - Defense World
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating - TipRanks
UBS raises Insmed stock price target to $110 By Investing.com - Investing.com UK
Insmed CEO Lewis sells $1.99 million in stock By Investing.com - Investing.com Australia
Insmed CEO Lewis sells $1.99 million in stock - Investing.com India
Amalgamated Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
RBC Capital starts Insmed at Outperform on brensocatib launch momentum - MSN
Guggenheim Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat
Investor Network: Insmed Incorporated to Host Earnings Call - ACCESS Newswire
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - Pink Sheet
Truist Financial Corp Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed (NASDAQ:INSM) Now Covered by Royal Bank of Canada - MarketBeat
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - MSN
RBC Capital Initiates Coverage of Insmed (LSE:0JAV) with Outperform Recommendation - Nasdaq
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga India
RBC Capital sets $100 price target on Insmed stock with Outperform rating - Investing.com Canada
RBC Capital Initiates Coverage of Insmed (INSM) with Outperform Recommendation - MSN
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says -February 25, 2025 at 12:09 pm EST - Marketscreener.com
FDA sets PDUFA date for Insmed's bronchiectasis drug By Investing.com - Investing.com Australia
FDA sets PDUFA date for Insmed’s bronchiectasis drug By Investing.com - Investing.com Nigeria
Insmed’s Brensocatib Receives FDA Priority Review - TipRanks
International Markets and Insmed (INSM): A Deep Dive for Investors - Yahoo Finance
FDA sets PDUFA date for Insmed's bronchiectasis drug - Investing.com India
FDA sets PDUFA date for Insmed’s bronchiectasis drug - Investing.com
Could This Novel Drug Transform Bronchiectasis Treatment? FDA Signals Confidence in Brensocatib - StockTitan
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
Insmed Inc (INSM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 17 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Mar 17 '25 |
Sale |
77.03 |
18,750 |
1,444,241 |
334,186 |
| Lewis William | Chair and CEO |
Mar 17 '25 |
Sale |
77.04 |
6,830 |
526,179 |
233,924 |
0.00%
2.17%
大文字化:
|
ボリューム (24 時間):